Laryngeal Cancer (LC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Laryngeal cancer (LC) represents one-third of all head and neck cancers and is a significant cause of morbidity and mortality. They can involve different subsites of the larynx, with varying implications in symptomatic presentation, patterns of spread, and treatment paradigms. Early-stage disease is highly curable with surgical or radiation monotherapy, often larynx-preserving. In contrast, the late-stage disease has a worse outcome, warrants multimodal therapy, and is less often larynx-preserving. The laryngeal cancers vast majority are well-differentiated squamous cell carcinoma. A minority of cases show squamous cell variants, including neuroendocrine carcinoma, sarcomatoid carcinoma, and verrucous carcinoma. Historically, verrucous and sarcomatoid carcinomas were thought to be radioresistant, though recent experience contradicts this notion. Spread patterns depend on the location of the primary mass and the inherent lymphatic supply at that location. Laryngeal cancers are divided into glottic, supraglottic, and subglottic subsites, with pathophysiology and treatment differing according to the subsite.
·
The incidence of Laryngeal cancer ranges from
4 to 5 cases per 100,000 population in the USA. The average age of the patients
is 65, with males outnumbering females.
Thelansis’s “Laryngeal Cancer (LC)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Laryngeal
Cancer (LC) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Laryngeal Cancer (LC) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Laryngeal Cancer (LC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment